541 related articles for article (PubMed ID: 21482566)
21. Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial.
Zhuo C; Huang Y; Liu W; Xu JF; Zhu WY; Stone GG; Yan JL; Mohamed N
Infect Drug Resist; 2022; 15():605-617. PubMed ID: 35237053
[TBL] [Abstract][Full Text] [Related]
22. [Ceftaroline fosamil in community-acquired and nosocomial pneumonia].
Calbo E; Zaragoza R
Enferm Infecc Microbiol Clin; 2014 Mar; 32 Suppl 2():38-43. PubMed ID: 24702978
[TBL] [Abstract][Full Text] [Related]
23. Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials.
Dryden M; Kantecki M; Yan JL; Stone GG; Leister-Tebbe H; Wilcox M
J Glob Antimicrob Resist; 2022 Mar; 28():108-114. PubMed ID: 34922058
[TBL] [Abstract][Full Text] [Related]
24. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
[TBL] [Abstract][Full Text] [Related]
25. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.
Welte T; Kantecki M; Stone GG; Hammond J
Int J Antimicrob Agents; 2019 Oct; 54(4):410-422. PubMed ID: 31404620
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia.
Chaudhary M; Ayub SG; Mir MA;
J Infect Public Health; 2018; 11(5):691-697. PubMed ID: 29803638
[TBL] [Abstract][Full Text] [Related]
27. A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection.
Korczowski B; Antadze T; Giorgobiani M; Stryjewski ME; Jandourek A; Smith A; O'Neal T; Bradley JS
Pediatr Infect Dis J; 2016 Aug; 35(8):e239-47. PubMed ID: 27164462
[TBL] [Abstract][Full Text] [Related]
28. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials.
Shorr AF; Kollef M; Eckburg PB; Llorens L; Friedland HD
Diagn Microbiol Infect Dis; 2013 Mar; 75(3):298-303. PubMed ID: 23357290
[TBL] [Abstract][Full Text] [Related]
29. Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review.
El Hajj MS; Turgeon RD; Wilby KJ
Int J Clin Pharm; 2017 Feb; 39(1):26-32. PubMed ID: 28058593
[TBL] [Abstract][Full Text] [Related]
30. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Poon H; Chang MH; Fung HB
Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
[TBL] [Abstract][Full Text] [Related]
31. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.
Cheng K; Pypstra R; Yan JL; Hammond J
J Antimicrob Chemother; 2019 Apr; 74(4):1086-1091. PubMed ID: 30597021
[TBL] [Abstract][Full Text] [Related]
32. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil.
Li J; Das S; Zhou D; Al-Huniti N
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):682-694. PubMed ID: 31044546
[TBL] [Abstract][Full Text] [Related]
33. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
Ortiz-Ruiz G; Caballero-Lopez J; Friedland IR; Woods GL; Carides A;
Clin Infect Dis; 2002 Apr; 34(8):1076-83. PubMed ID: 11914996
[TBL] [Abstract][Full Text] [Related]
34. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
[TBL] [Abstract][Full Text] [Related]
35. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Casapao AM; Steed ME; Levine DP; Rybak MJ
Expert Opin Pharmacother; 2012 Jun; 13(8):1177-86. PubMed ID: 22594846
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
Lan SH; Chang SP; Lai CC; Lu LC; Chao CM
J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31181859
[TBL] [Abstract][Full Text] [Related]
37. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.
Kaye KS; Udeani G; Cole P; Friedland HD
Hosp Pract (1995); 2015; 43(3):144-9. PubMed ID: 25956849
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
39. Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE.
Carreno JJ; Lodise TP
Infect Dis Ther; 2014 Dec; 3(2):123-32. PubMed ID: 25193094
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG
J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
